Medical Principles and Practice · 2004 · 18 citations · 15 references
Life SciencesImmunologyInfectious DiseasesClinical ImmunologyInflammationInnate ImmunityAntiviral ImmunityInnate Immune ActivationPlatelet ActivationPlatelet FunctionViral HepatitisPlatelet-activating Factor Signaling
OBJECTIVE: The aim of this study was to determine tumor necrosis factor alpha (TNF-alpha) and interleukin-6 (IL-6) release in response to platelet-activating factor (PAF) induction in peripheral blood mononuclear cells (PBMCs) from chronic hepatitis B virus (HBV) carriers. METHODS: Subjects were grouped into three subgroups. The mean age was 37 +/- 10 years. Group A (n = 15), group B (n = 10) and group C (n = 9) subjects were HBV serology-negative, had natural immunity after recovery from an acute HBV infection, and were chronic HBV carriers, respectively. RESULTS: Compared with group A, PBMCs from naturally immune subjects and chronic HBV carriers produced significantly higher amounts of TNF-alpha and IL-6 in response to PAF. In chronic HBV carriers, TNF-alpha (1,633.3 +/- 793.7) and IL-6 (2,533.3 +/- 466.3) production was statistically lower than TNF-alpha (2,630.0 +/- 727.3) and IL-6 (3,870.0 +/- 728.4) obtained from naturally immune subjects to HBV. CONCLUSION: Differences of TNF-alpha levels between chronic HBV carriers and naturally immune subjects suggest that TNF-alpha may be a critical mediator of HBV clearance.
15
CELLULAR IMMUNITY AND HEPATITIS-ASSOCIATED, AUSTRALIA ANTIGEN LIVER DISEASE
F. J. Dudley, Roy Fox, S. Sherlock · The Lancet · 1972 · 489 citations
Medicine, Immunology, Pathology +14
Effects of cytokines on the liver
Tilo Andus, Joachim Bauer, W. Gerok · Hepatology · 1991 · 408 citations · Full text